Guardant Health, (GH), a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. All of the shares in the offering will be sold by Guardant Health. In addition, Guardant Health expects to grant the underwriters a option to purchase an additional 675,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
J.P. Morgan Securitie and BofA Merrill Lynch are serving as joint book-running managers for the proposed offering.
Related Reports and Monitors
Edge Emitting Lasers: Market and Technology Trends 2019
Market & Technology
Nanopore Sequencing 2019 – Patent Landscape Analysis